| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Baird Medical Investment Holdings Ltd
$1.26
+0.04 (+3.28%)
Market Cap
53.18 M
EPS
-0.98
P/E Ratio
-
Value Trade
87.68 K
17.76 %
Week
11.5 %
1 Month
-25 %
3 Month
24.75 %
6 Month
-83.45 %
5 Year
-83.45 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
15.51 K
52 Week Range
0.76 - 3.75
% held by Insiders
56.52 %
% held by Institutions
7.32 %
Enterprise Value
85.38 M
Total Shares
42.21 M
Short %
0.13 %
Float Shares
15.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Baird Medical Investment Holdings Ltd
4Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
▲First Patient DosedTrial
Subscribe to view catalyst details
TBD
▲First Patient DosedTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BDMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BDMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BDMD▲ +3.3%today
Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally
Baird Medical and Alpmed have formed a strategic partnership to enhance the global development and commercialization of irreversible electroporation (IRE) technology. The collaboration aims to leverage Baird's regulatory expertise and Alpmed's innovation in IRE to create advanced ablation solutions. They plan to submit a 510(k) application to the FDA by the end of 2026 for a device targeting soft tissue tumors.
Read more →BDMD▲ +7.5%on this news
Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina
Baird Medical has successfully completed its first microwave ablation procedures in Vietnam and Argentina, marking a significant step in its global expansion strategy. The procedures were performed by experienced medical professionals, showcasing the effectiveness of the company's minimally invasive technology. This development highlights Baird Medical's commitment to providing innovative treatment options worldwide.
Read more →BDMDBaird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion
Baird Medical has announced the relocation of its global headquarters to New York City to enhance its U.S. operations and support its growth strategy. This move follows the appointment of Mark Saxton as CEO of the U.S. subsidiary, aiming to strengthen the company's market presence. The headquarters will serve as a central hub for corporate leadership and strategic initiatives, facilitating better access to healthcare investors.
Read more →BDMD▲ +8.6%on this news
Baird Medical Expands Global Reach with Regulatory Clearance in Argentina
Baird Medical has received regulatory clearance for its Microwave Ablation systems in Argentina, marking a significant step in its international expansion efforts. This approval complements existing certifications in the U.S. and several Asian countries. The company is also pursuing additional registrations in various key markets, aiming to meet the growing global demand for minimally invasive therapies.
Read more →BDMDBAIRD MEDICAL INVESTMENT HOLDINGS LIMITED INDEX TO FINANCIAL STATEMENTS Page Baird Medical Investment Holdings Limited Unaudited Interim Condensed Consolidated Balance Sheets as of
Baird Medical Investment Holdings Limited released its unaudited interim financial statements for the six months ending June 30, 2025. Financial results indicate a substantial decline, with a reported net loss of approximately $11.36 million, contrasting with a profit of $4.33 million in the previous year. The total assets decreased slightly from about $77.96 million at the end of December 2024 to approximately $76.99 million by June 30, 2025. Major increases in operating expenses were noted, particularly in general administration and research and development.
Read more →BDMDBaird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting
Baird Medical will participate in the American Thyroid Association Annual Meeting from October 30 to November 3, 2024, in Chicago. The company will showcase its microwave ablation technology at Booth 100 and host a presentation on advancements in thyroid treatment. This participation emphasizes Baird Medical's expansion into the U.S. market following FDA clearance for its devices.
Read more →BDMD▼ -12.9%on this newsshared move
Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024
Baird Medical Investment Holdings Ltd. reported preliminary financial results for the first half of 2024, showing a 13.8% increase in revenues and an 85.8% rise in net income. The company is optimistic about its expansion into the U.S. market following recent FDA clearances for its microwave ablation technology. This technology is seen as a promising alternative to traditional thyroidectomy for patients with benign thyroid tumors.
Read more →BDMD▼ -6.9%on this news· ran to -19% by day 3shared move
Baird Medical Lists in the U.S. on the Nasdaq Exchange
Baird Medical Investment Holdings Ltd. has successfully listed on the Nasdaq under the ticker BDMD, marking a significant milestone as it transitions to a public company. The company, known for its microwave ablation technology, aims to address unmet needs in the U.S. thyroid care market following recent FDA clearances. Co-Founder Wenyuan Wu celebrated the occasion by ringing the Opening Bell.
Read more →BDMDBaird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference
Baird Medical Investment Holdings Ltd. will participate in Roth's 3rd Annual Healthcare Opportunities Conference on October 9, 2024. The company, which specializes in microwave ablation technology, has recently expanded into the U.S. market after receiving FDA 510(k) clearances. Their technology presents a viable alternative to thyroidectomy for patients with benign thyroid tumors.
Read more →BDMDBaird Medical and ExcelFin Acquisition Corp Complete Business Combination
Baird Medical and ExcelFin Acquisition Corp have successfully completed their business combination, resulting in the formation of Baird Medical Investment Holdings Limited, which will start trading on Nasdaq under the ticker BDMD. The decision to merge received overwhelming support, with 99.9% of votes in favor during a special stockholder meeting. Following this acquisition, Baird Medical aims to expand its presence in the U.S. market, having recently obtained FDA clearance for its microwave ablation devices used in treating tumors. However, potential risks related to market expansion and recognition of expected benefits pose challenges.
Read more →Competitive Position
How BDMD ranks across every disease it competes inCompetitive Position is a premium feature
See how BDMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial